🌏 𝐉𝐨𝐢𝐧 𝐔𝐬 𝐚𝐭 𝐭𝐡𝐞 𝐈𝐧𝐝𝐢𝐚 𝐏𝐚𝐯𝐢𝐥𝐢𝐨𝐧 𝐚𝐭 𝐁𝐈𝐎 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧 2026! ABLE cordially invites you to visit the India Pavilion Booths #3351 & #3551 at the BIO International Convention 2026. ABLE is proud to present an expanded and more impactful India Pavilion, spanning over 5,000 sq. ft., in collaboration with 3SMG Pvt. Ltd., showcasing the strength, innovation and global potential of India's biotechnology ecosystem. 📅 June 22-25, 2026 📍 San Diego Convention Center, USA The India Pavilion brings together India's leading biotech companies, innovation enablers, research institutions, and government stakeholders to showcase cutting-edge advancements, foster meaningful dialogue, build strategic partnerships, and explore new opportunities for global collaboration and investment. We look forward to welcoming you!

ABLE is once again organizing the India Pavilion at BIO International Convention. This year, the India Pavilion spans over 5,000 sq. ft. and features participation from more than 50 Indian biotechnology and life sciences companies. We warmly invite you to visit the India Pavilion to explore potential collaboration, partnership, investment, and business opportunities with leading Indian biotech companies. To facilitate visits and interactions, ABLE has a limited number of complimentary exhibition access invites that provide entry to the exhibition area on all four days of the event. Interested participants may kindly reach out at the earliest to: Dr. Balasubramanya S. General Manager, ABLE Mobile: 91 99000 48833 Email: gm@ableindia.org.in Kindly note that the issuance of complimentary passes will be solely at the discretion of ABLE and subject to availability.

🌍 𝐀𝐝𝐯𝐞𝐫𝐭𝐢𝐬𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐈𝐧𝐝𝐢𝐚 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐇𝐚𝐧𝐝𝐛𝐨𝐨𝐤 2026 The BIO International Convention 2026, happening from June 22–25 in San Diego, is one of the world’s most influential biotechnology gatherings, bringing together innovators, investors, policymakers, and industry leaders from across the globe. 𝐀𝐁𝐋𝐄 𝐢𝐬 𝐨𝐫𝐠𝐚𝐧𝐢𝐳𝐢𝐧𝐠 𝐭𝐡𝐞 𝐈𝐧𝐝𝐢𝐚 𝐏𝐚𝐯𝐢𝐥𝐢𝐨𝐧 𝐢𝐧 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 3𝐒𝐌𝐆 𝐏𝐯𝐭. 𝐋𝐭𝐝., highlighting the strength and innovation of India’s biotech ecosystem on an international platform. 📘 𝐓𝐡𝐞 𝐈𝐧𝐝𝐢𝐚 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐇𝐚𝐧𝐝𝐛𝐨𝐨𝐤 2026 𝐰𝐢𝐥𝐥 𝐬𝐞𝐫𝐯𝐞 𝐚𝐬 𝐚 𝐩𝐫𝐞𝐦𝐢𝐞𝐫 𝐬𝐡𝐨𝐰𝐜𝐚𝐬𝐞 𝐨𝐟: ▪️ India’s growing bioeconomy and innovation landscape ▪️ Emerging biotech startups and breakthrough technologies ▪️ Insights into BioPharma, MedTech, BioAgri & Industrial Biotech ▪️ Policy, regulatory and investment opportunities ▪️ Key ecosystem enablers driving sector growth ✨ 𝐖𝐡𝐲 𝐩𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞? ▪️ Strengthen your global visibility ▪️ Reach investors, collaborators & decision-makers ▪️ Feature your organization at India-focused engagements during BIO 2026 ▪️ Gain promotion through ABLE’s digital outreach and global partner network 🎯 𝐒𝐩𝐞𝐜𝐢𝐚𝐥 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬: ▪️ Startup Offer – 15% discount 1-year ABLE membership ▪️ Digital promotion opportunities including video features and newsletter spotlights A valuable opportunity to position your organization on the global biotech stage and connect with the international innovation ecosystem. 📩 𝐓𝐨 𝐩𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞, 𝐜𝐨𝐧𝐧𝐞𝐜𝐭 𝐰𝐢𝐭𝐡 Dr. Balasubramanya S (gm@ableindia.org.in) and Pavana Praveen (pavanapr@ableindia.org.in)

🎯 Join us for the Webinar on “𝐀𝐱𝐢𝐨𝐦 𝐌𝐢𝐬𝐬𝐢𝐨𝐧 𝟒: 𝐄𝐧𝐚𝐛𝐥𝐢𝐧𝐠 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐁𝐢𝐨𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐒𝐩𝐚𝐜𝐞” The 𝐂𝐨𝐄 𝐒𝐩𝐚𝐜𝐞 𝐓𝐞𝐜𝐡 𝐅𝐨𝐮𝐧𝐝𝐚𝐭𝐢𝐨𝐧, 𝐁𝐞𝐧𝐠𝐚𝐥𝐮𝐫𝐮, in collaboration with ABLE - Association of Biotechnology Led Enterprises as the Biotech Industry Knowledge Partner and Helogen Corporation as the Industry Partner, invites you to the 3rd webinar under the “𝐒𝐩𝐚𝐜𝐞 𝐭𝐨 𝐒𝐨𝐜𝐢𝐞𝐭𝐲” series. 📅 𝐃𝐚𝐭𝐞: 22 May 2026 ⏰ 𝐓𝐢𝐦𝐞: 05:00 – 06:30 PM (IST) Building on our previous sessions on 𝐒𝐩𝐚𝐜𝐞 𝐁𝐢𝐨𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 and 𝐓𝐡𝐞 𝐫𝐨𝐥𝐞 𝐨𝐟 𝐬𝐩𝐚𝐜𝐞 𝐬𝐭𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐬𝐜𝐚𝐥𝐢𝐧𝐠 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡, this third webinar brings a real mission perspective highlighting how international human spaceflight missions are already enabling biomedical experiments, validating research workflows and accelerating global partnerships in low Earth orbit. This session will focus on the practical lessons emerging from Axiom Mission 4 and how collaborative missions are shaping the future of biomedical science in space by enabling: 🧬 Validation of biomedical experiments in microgravity 🚀 International payload integration and mission operations 🌍 Country-led research partnerships through crewed missions 🔬 Translational pathways from space research to healthcare innovation 🌍 India’s growing role in human spaceflight-enabled life science research The panel discussion will provide firsthand insights into ongoing biomedical payloads, operational experiences from international missions and how such collaborations are creating a pathway for India’s future in space-enabled biotechnology, translational medicine and orbital R&D. 🎙️𝐒𝐩𝐞𝐚𝐤𝐞𝐫𝐬: ▪️𝐃𝐫. 𝐏𝐞𝐠𝐠𝐲 𝐖𝐡𝐢𝐭𝐬𝐨𝐧 – Astronaut & Vice President, Human Spaceflight, Axiom Space ▪️𝐃𝐫. 𝐁𝐇𝐌 𝐃𝐚𝐫𝐮𝐤𝐞𝐬𝐡𝐚 – Senior Scientist, Human Space Flight Center, ISRO ▪️𝐃𝐫. 𝐒𝐡𝐢𝐫𝐞𝐞𝐬𝐡 𝐒𝐫𝐢𝐯𝐚𝐬𝐭𝐚𝐯𝐚 – Group Leader, Systems Biology for Biofuel Group, ICGEB ▪️𝐃𝐫. 𝐃𝐚𝐫𝐢𝐮𝐬𝐳 𝐙𝐚𝐩𝐚ł𝐚 – Co-founder & CSO, CortiVision sp. z o.o. ▪️𝐏𝐞𝐚𝐫𝐥𝐲 𝐏𝐚𝐧𝐝𝐲𝐚 – Director, International Government Business, Axiom Space (𝘔𝘰𝘥𝘦𝘳𝘢𝘵𝘰𝘳) 🔗 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐡𝐞𝐫𝐞: shorturl.at/g499F Join us to understand how space-bio missions are moving beyond concept to execution - demonstrating how biomedical innovation in space is becoming a strategic platform for international collaboration, translational research and the next phase of India’s space biotechnology journey.

We are pleased to share that @able_president, Mr. G S Krishnan, will be joining as a panelists at the 𝐑𝐄𝐂𝐄𝐈𝐂 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 & 𝐀𝐰𝐚𝐫𝐝𝐬 2026 in the session “𝐁𝐞𝐲𝐨𝐧𝐝 𝐋𝐚𝐧𝐝𝐟𝐢𝐥𝐥𝐬: 𝐑𝐞𝐢𝐦𝐚𝐠𝐢𝐧𝐢𝐧𝐠 𝐈𝐧𝐝𝐢𝐚’𝐬 𝐑𝐞𝐬𝐨𝐮𝐫𝐜𝐞 𝐑𝐞𝐜𝐨𝐯𝐞𝐫𝐲 𝐅𝐮𝐭𝐮𝐫𝐞” on 21st April 2026. 🌍The session will explore key challenges across financial, regulatory, operational, and skill-related areas, while highlighting opportunities for municipalities and industry to collaborate. The discussion aims to outline actionable pathways to build a financially viable, environmentally compliant, and circular recovery ecosystem, reducing landfill dependency and strengthening material recovery systems. Looking forward to an insightful and engaging session. @ficci_india

🌍 𝐈𝐧𝐝𝐢𝐚’𝐬 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐄𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 𝐀𝐭𝐭𝐫𝐚𝐜𝐭𝐢𝐧𝐠 𝐆𝐥𝐨𝐛𝐚𝐥 𝐓𝐚𝐥𝐞𝐧𝐭 India’s biotechnology sector is increasingly capturing the attention of international students, who are keen to explore its growing opportunities in research, innovation and industry. 𝐀𝐁𝐋𝐄 𝐡𝐚𝐬 𝐞𝐦𝐞𝐫𝐠𝐞𝐝 𝐚𝐬 𝐚 𝐤𝐞𝐲 𝐩𝐨𝐢𝐧𝐭 𝐨𝐟 𝐜𝐨𝐧𝐭𝐚𝐜𝐭, providing a unified platform for students and others to understand India’s biotech landscape, connect with industry stakeholders and explore academic and career pathways. As India continues to strengthen its position as a global biotech hub, this rising interest reflects both the country’s scientific advancements and the expanding opportunities within its BioEconomy.

🚀 𝐒𝐡𝐨𝐰𝐜𝐚𝐬𝐞 𝐘𝐨𝐮𝐫 𝐁𝐫𝐚𝐧𝐝 𝐚𝐭 𝐁𝐈𝐎 2026, 𝐒𝐚𝐧 𝐃𝐢𝐞𝐠𝐨 by 𝐀𝐝𝐯𝐞𝐫𝐭𝐢𝐬𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐈𝐧𝐝𝐢𝐚 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐇𝐚𝐧𝐝𝐛𝐨𝐨𝐤 2026 𝐁𝐈𝐎 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧 2026, the world’s premier biotechnology event, will take place from June 22–25, 2026. 𝐀𝐁𝐋𝐄 𝐢𝐬 𝐨𝐫𝐠𝐚𝐧𝐢𝐳𝐢𝐧𝐠 𝐭𝐡𝐞 𝐈𝐧𝐝𝐢𝐚 𝐏𝐚𝐯𝐢𝐥𝐢𝐨𝐧 𝐢𝐧 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 3𝐒𝐌𝐆 𝐏𝐯𝐭. 𝐋𝐭𝐝., presenting India’s dynamic biotech ecosystem to global stakeholders. 🌍 𝐂𝐚𝐧’𝐭 𝐚𝐭𝐭𝐞𝐧𝐝 𝐢𝐧 𝐩𝐞𝐫𝐬𝐨𝐧? You can still gain powerful global visibility through the India Biotech Handbook 2026, to be launched at the India Pavilion. 📘 𝐖𝐡𝐲 𝐭𝐡𝐞 𝐈𝐧𝐝𝐢𝐚 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐇𝐚𝐧𝐝𝐛𝐨𝐨𝐤? A premium publication showcasing: ▪️India’s bioeconomy growth & global positioning ▪️Emerging startups and breakthrough innovations ▪️Policy and regulatory landscape ▪️Sector insights across BioPharma, BioAgri, MedTech & Industrial Biotech ▪️Investment opportunities and ecosystem enablers 🌟 𝐖𝐡𝐚𝐭 𝐘𝐨𝐮 𝐆𝐚𝐢𝐧 ▪️Global visibility among investors, policymakers & industry leaders ▪️Distributed in the India Pavilion and all India-focused engagements at BIO 2026 ▪️Promotion across ABLE’s digital platforms ▪️Circulated among global biotech agencies and partner ecosystems 🎯 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 ▪️Early Bird: 10% discount (till May 15, 2026) ▪️Startup Offer: 15% discount 1 year ABLE membership ▪️Digital Boost: 1-minute video feature 🎥 ▪️Newsletter Spotlight 💡 𝐖𝐡𝐲 𝐏𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞? Position your brand on the global stage, showcase innovations and connect with international partners, all in a cost-effective way. We would be delighted to feature your organization in this prestigious global publication. 📩 𝐑𝐞𝐚𝐜𝐡 𝐨𝐮𝐭 𝐭𝐨 𝐜𝐨𝐧𝐟𝐢𝐫𝐦 𝐲𝐨𝐮𝐫 𝐩𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐢𝐨𝐧 to 𝐃𝐫. 𝐁𝐚𝐥𝐚𝐬𝐮𝐛𝐫𝐚𝐦𝐚𝐧𝐲𝐚 𝐒 (gm@ableindia.org.in) or 𝐏𝐚𝐯𝐚𝐧𝐚 𝐏𝐫𝐚𝐯𝐞𝐞𝐧 (pavanapr@ableindia.org.in)

🚀 Join us for the Webinar on "𝐁𝐢𝐨𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐢𝐧 𝐒𝐩𝐚𝐜𝐞 – 𝐈𝐧𝐝𝐢𝐚’𝐬 𝐑𝐨𝐚𝐝 𝐭𝐨 𝐭𝐡𝐞 𝐍𝐞𝐱𝐭 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫" The 𝐂𝐞𝐧𝐭𝐞𝐫 𝐨𝐟 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 (𝐂𝐎𝐄) 𝐒𝐩𝐚𝐜𝐞 𝐓𝐞𝐜𝐡 𝐅𝐨𝐮𝐧𝐝𝐚𝐭𝐢𝐨𝐧, 𝐁𝐚𝐧𝐠𝐚𝐥𝐨𝐫𝐞, in collaboration with the ABLE, is organizing a webinar under the “𝐒𝐩𝐚𝐜𝐞 𝐭𝐨 𝐒𝐨𝐜𝐢𝐞𝐭𝐲” series. This initiative aims to serve as a high-level think tank and collaborative platform to bridge the gap between the space sector and mainstream industries, with a focus on pharmaceuticals, semiconductors and advanced manufacturing. 🗓 𝐃𝐚𝐭𝐞: Friday, 27 March 2026 ⏰𝐓𝐢𝐦𝐞: 10:00 AM – 11:30 AM (IST) The webinar will bring together experts to discuss how space infrastructure, automated laboratory technologies, and microgravity research are enabling new opportunities in biopharmaceutical discovery, biomedical innovation, and the future of in-space manufacturing. 🎙 𝐒𝐩𝐞𝐚𝐤𝐞𝐫𝐬: 🔹𝐌𝐫. 𝐆𝐨𝐯𝐢𝐧𝐝𝐚𝐫𝐚𝐣𝐚𝐧 𝐃 𝐒 – Director, CoE Space Tech Foundation 🔹𝐌𝐫. 𝐆 𝐒 𝐊𝐫𝐢𝐬𝐡𝐧𝐚𝐧 – Hon. President, ABLE 🔹𝐌𝐫. 𝐆𝐞𝐨𝐫𝐠𝐞 𝐖𝐞𝐢𝐧𝐦𝐚𝐧𝐧 – Founder, Astroworks Ventures (𝘔𝘰𝘥𝘦𝘳𝘢𝘵𝘰𝘳) 🔹𝐂𝐚𝐩𝐭𝐚𝐢𝐧 𝐀𝐛𝐡𝐢𝐣𝐢𝐭 𝐁𝐡𝐮𝐭𝐞𝐲 (𝐑𝐞𝐭𝐝.) – Co-Founder, Inbound Aerospace 🔹𝐃𝐫. 𝐃𝐚𝐯𝐢𝐝𝐞 𝐌𝐚𝐫𝐨𝐭𝐭𝐚 – Chief Science Officer, Helogen Corporation 🔹𝐃𝐫. 𝐌𝐚𝐧𝐚𝐬𝐡 𝐊. 𝐏𝐚𝐮𝐥 – Associate Professor, Manipal School of Life Sciences, MAHE 🔗 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐡𝐞𝐫𝐞: lnkd.in/gMKdj9EP 🌍 Join us for an engaging discussion on India’s journey toward the next frontier of space-enabled biomanufacturing.

Dr. Jitendra Singh, Hon’ble Minister of State (Independent Charge), Ministry of Science & Technology, launched the India Bioeconomy Report (IBER) 2026 and the BIRAC Impact Report on 14th Foundation day of BIRAC. He shared the highlights from the sector’s transformative growth and future potential, as reflected in the India Bioeconomy Report 2026. He said, “The highlight of this year’s Foundation Day of BIRAC is that, as per the India Bio Economy Report released today, India achieves a quantum rise in bio-economy, touching the figure of 195.3 billion U.S. dollars. This is significant, particularly because before the Modi government came in 2014, India's bio-economy stood at mere 10 billion U.S. dollars, which means that there has been a nearly 20 times hike in just over a decade. This milestone is in keeping with the collective realization that the next industrial revolution is going to be biotechnology driven and the entire paradigm of economic growth is going to shift from IT to majorly Biotech and, when that happens, India would have already taken a lead. Similarly, while in 2014 the number of biotech StartUps in this country was just around 400, today it is nearly 12,000, which is again quite a record.” He added, “While congratulating the entire fraternity and the industry for this synergised effort, it is important to mention that, this success story has been possible primarily because of an enabling milieu and patronage provided by PM Shri Narendra Modi, who not only made sure that India was among the first few countries in the world to launch a dedicated Biotechnology policy called BioE3, but he also made it a point to publicly announce this in his Independence Day address of 2025, calling upon the youth of the country to explore the biotechnology sector to discover a bright future for themselves”. The address reflected the growing momentum of India’s bio-economy and reinforced the country’s position as a key driver in the global biotechnology landscape. @DrJitendraSingh @rajesh_gokhale @drjitendrak170 @IndiaDST @DBTIndia @BIRAC_2012

India #BioEconomy report 2026 prepared by #ABLE was released by Hon. Minister @DrJitendraSingh . The 2025 #BioEconomy value is $195.3 billion, @18% growth contributing to 4.8% GDP. #BioIndustrial - 46% and #BioPharma - 33% are the major contributors. @kiranshaw @Muralipm

𝐑𝐞𝐥𝐞𝐚𝐬𝐞 𝐨𝐟 𝐓𝐚𝐦𝐢𝐥 𝐍𝐚𝐝𝐮 𝐁𝐢𝐨𝐕𝐢𝐬𝐢𝐨𝐧 2026 – 𝐒𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐁𝐢𝐨𝐞𝐜𝐨𝐧𝐨𝐦𝐲 Tamil Nadu BioVision 2026 was released by 𝐓𝐡𝐢𝐫𝐮. 𝐌.𝐊. 𝐒𝐭𝐚𝐥𝐢𝐧, Hon’ble Chief Minister of Tamil Nadu yesterday. 𝐓𝐡𝐢𝐫𝐮 𝐔𝐝𝐡𝐚𝐲𝐚𝐧𝐢𝐝𝐡𝐢 𝐒𝐭𝐚𝐥𝐢𝐧, Hon’ble Deputy Chief Minister of Tamil Nadu; 𝐌𝐫. 𝐍. 𝐌𝐮𝐫𝐮𝐠𝐚𝐧𝐚𝐧𝐭𝐡𝐚𝐦, 𝐈.𝐀.𝐒., Chief Secretary, Government of Tamil Nadu; 𝐌𝐫. 𝐒𝐚𝐣𝐣𝐚𝐧 𝐑 𝐂𝐡𝐚𝐯𝐚𝐧 𝐈𝐀𝐒, Secretary, Planning and Development Department, Government of Tamil Nadu; 𝐃𝐫. 𝐉. 𝐉𝐞𝐲𝐚𝐫𝐚𝐧𝐣𝐚𝐧, Acting Vice-Chairman of State Planning Commission and 𝐓𝐦𝐭. 𝐒𝐮𝐝𝐡𝐚 𝐑𝐚𝐦𝐞𝐧 𝐈𝐅𝐒, Member Secretary of State Planning Commission, Government of Tamil Nadu were present. The report was prepared by 𝐀𝐁𝐋𝐄 for the 𝐓𝐚𝐦𝐢𝐥 𝐍𝐚𝐝𝐮 𝐒𝐭𝐚𝐭𝐞 𝐏𝐥𝐚𝐧𝐧𝐢𝐧𝐠 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧, 𝐆𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐨𝐟 𝐓𝐚𝐦𝐢𝐥 𝐍𝐚𝐝𝐮 highlighting 𝐓𝐚𝐦𝐢𝐥 𝐍𝐚𝐝𝐮’𝐬 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 to emerge as a 𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥𝐥𝐲 𝐚𝐧𝐝 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐁𝐢𝐨𝐄𝐜𝐨𝐧𝐨𝐦𝐲 𝐡𝐮𝐛, driven by BioPharma and biomanufacturing, BioIndustrial and fermentation-based industries, medical devices, BioAgri and emerging circular bioeconomy opportunities. Tamil Nadu BioVision 2026 outlines a strategic roadmap to position the 𝐁𝐢𝐨𝐄𝐜𝐨𝐧𝐨𝐦𝐲 𝐚𝐬 𝐚 𝐤𝐞𝐲 𝐝𝐫𝐢𝐯𝐞𝐫 𝐨𝐟 𝐭𝐡𝐞 𝐒𝐭𝐚𝐭𝐞’𝐬 𝐓𝐫𝐢𝐥𝐥𝐢𝐨𝐧 𝐃𝐨𝐥𝐥𝐚𝐫 𝐕𝐢𝐬𝐢𝐨𝐧. Building on Tamil Nadu’s strong manufacturing base, globally competitive pharma and healthcare ecosystem and robust research institutions, the vision aims to accelerate innovation, high-value manufacturing and export competitiveness. It prioritizes investment-led growth, skilled job creation, regional cluster development beyond Chennai. 📥 Download the report here: lnkd.in/gdRCYsjr

🌍 𝐉𝐨𝐢𝐧 𝐭𝐡𝐞 𝐈𝐧𝐝𝐢𝐚 𝐏𝐚𝐯𝐢𝐥𝐢𝐨𝐧 𝐚𝐭 𝐁𝐈𝐎 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧 2026 The BIO International Convention 2026, is the world’s largest and most influential biotechnology gathering that will take place from 22–25 𝐉𝐮𝐧𝐞 2026 in 𝐒𝐚𝐧 𝐃𝐢𝐞𝐠𝐨, 𝐂𝐚𝐥𝐢𝐟𝐨𝐫𝐧𝐢𝐚, 𝐔𝐒𝐀. ABLE is leading the India Pavilion at the convention, spread across 5,000 sq. ft. in collaboration with 3𝐒𝐌𝐆 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐋𝐢𝐦𝐢𝐭𝐞𝐝. The Pavilion, located at 𝐁𝐨𝐨𝐭𝐡 𝐍𝐨𝐬. 3351 𝐚𝐧𝐝 3551, is strategically positioned in a high-traffic zone to ensure maximum visibility, networking opportunities, and engagement with global biotech leaders and delegates. A high-level Indian delegation comprising senior government officials, biotech CEOs, academic leaders and innovative startups is expected to participate, further strengthening India’s global presence in biotechnology. We warmly invite Government Departments (State & Union), PSUs, Corporates, R&D Institutions, Universities, SMEs and Startups to join the India Pavilion and connect with the global biotech ecosystem. For more information, lnkd.in/gNVGgN4U 📩 For participation and enquiries, please contact: 𝐃𝐫. 𝐁𝐚𝐥𝐚𝐬𝐮𝐛𝐫𝐚𝐦𝐚𝐧𝐲𝐚 𝐒 (𝐀𝐁𝐋𝐄) 📞 91 99000 48833 📧 gm@ableindia.org.in 𝐌𝐫. 𝐒𝐮𝐬𝐚𝐧𝐭𝐚 𝐌𝐚𝐡𝐚𝐩𝐚𝐭𝐫𝐚 (3𝐒𝐌𝐆 𝐄𝐯𝐞𝐧𝐭𝐬) 📞 91 99719 88322 📧 md@3smg.in

𝐀𝐁𝐋𝐄 𝐚𝐭 𝐑𝐚𝐣𝐚𝐬𝐭𝐡𝐚𝐧 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐨𝐧𝐜𝐥𝐚𝐯𝐞 2026 𝐃𝐫. 𝐁𝐚𝐥𝐚𝐬𝐮𝐛𝐫𝐚𝐦𝐚𝐧𝐲𝐚 𝐒, General Manager of ABLE, was among the distinguished panelists at the 𝐑𝐚𝐣𝐚𝐬𝐭𝐡𝐚𝐧 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐨𝐧𝐜𝐥𝐚𝐯𝐞 2026, contributing to an insightful panel discussion on the theme “𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐟𝐨𝐫 𝐒𝐨𝐜𝐢𝐞𝐭𝐲: 𝐌𝐚𝐤𝐢𝐧𝐠 𝐁𝐢𝐨𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐀𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐥𝐞, 𝐈𝐧𝐜𝐥𝐮𝐬𝐢𝐯𝐞 & 𝐈𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥”. The session brought together leaders from academia, industry, and innovation ecosystems to deliberate on how biotechnology can address pressing societal challenges while fostering inclusive growth. The discussion highlighted how biotechnology can play a transformative role in sectors such as healthcare, agriculture, environmental sustainability, and food security. Panelists emphasized the importance of translating laboratory research into affordable, scalable solutions that can benefit communities at the grassroots level, particularly in rural and underserved regions. Strengthening industry–academia–startup collaborations, expanding incubation and funding opportunities, and enhancing policy support were also identified as key enablers for building a robust biotechnology ecosystem. The panel further underscored the need to promote scientific awareness and innovation literacy, while ensuring that biotechnology advances remain ethical, responsible, and sustainable. A key takeaway from the discussion was that biotechnology’s true success lies not only in scientific breakthroughs, but in its ability to deliver meaningful societal impact and improve quality of life.

🌱 The 𝐀𝐁𝐋𝐄 𝐁𝐢𝐨𝐄𝐜𝐨𝐧𝐨𝐦𝐲 𝐂𝐨𝐧𝐜𝐥𝐚𝐯𝐞 2026 concluded on a powerful and forward-looking note, reinforcing India’s ambition to become a global leader in the biodigital era. From AI-driven drug discovery and digital biofoundries to precision agriculture, marine biotechnology, deep-tech financing, and regulatory reform, the conclave emphasized that the convergence of biology and digital technologies will define India’s global leadership in sustainable healthcare, manufacturing, and planetary solutions. In the 𝐑𝐨𝐮𝐧𝐝𝐭𝐚𝐛𝐥𝐞 𝐃𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐨𝐧 ‘𝐂𝐨𝐧𝐯𝐞𝐫𝐠𝐞𝐧𝐜𝐞 𝐨𝐟 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐁𝐢𝐭𝐬’, experts explored how AI is reshaping genomics, drug discovery, synthetic biology, marine biotech, and agriculture. The focus was on responsible AI adoption, structured data ecosystems, climate resilience, and building future-ready biodigital talent to stay ahead in a fast-evolving global landscape. The 𝐕𝐢𝐤𝐬𝐢𝐭 𝐇𝐞𝐚𝐥𝐭𝐡 session, centered on India’s shift from generics to innovation-led, AI-powered healthcare. Topics included generative AI for protein design, mRNA platforms, digital twins in manufacturing, and personalized medicine. Regulatory agility and high-quality multimodal data were identified as key enablers. The 𝐁𝐢𝐨-𝐅𝐨𝐮𝐧𝐝𝐫𝐲 4.0 session highlighted the move from manual experimentation to AI-enabled, automated biomanufacturing. Digital twins, accelerated design-build-test-learn cycles, data transparency, alternative microbial chassis, and early scale-up planning were emphasized as critical for commercial success. The 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐀𝐠𝐫𝐢𝐜𝐮𝐥𝐭𝐮𝐫𝐞 session focused on AI-powered farm intelligence, geospatial mapping, soil health, and yield optimization. The session stressed farmer-centric innovation, trust-building, scalable digital infrastructure, and mission-mode collaboration to improve productivity and climate resilience. The 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 (𝐑𝐃𝐈) 𝐅𝐮𝐧𝐝 session was presented as a transformative deep-tech financing mechanism bridging the mid-stage funding gap. With blended models, co-investment, and scale-up support, it aims to de-risk innovation and prepare Indian biotech companies for global capital markets. In the 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐅𝐚𝐬𝐭-𝐭𝐫𝐚𝐜𝐤𝐢𝐧𝐠 session, speakers addressed regulatory bottlenecks and the need for harmonized, transparent, risk-based frameworks. AI-enabled review systems, capacity building, global alignment, and structured industry-government dialogue were seen as essential to match the speed of scientific innovation. 🚀 India stands at a strategic inflection point. To lead the biodigital era, we must align innovation, capital, policy, talent, and regulation.

LinkedIn 🏆 𝐀𝐁𝐋𝐄 𝐁𝐢𝐨𝐄𝐧𝐭𝐫𝐞𝐩𝐫𝐞𝐧𝐞𝐮𝐫 𝐨𝐟 𝐭𝐡𝐞 𝐘𝐞𝐚𝐫 2026 For the first time, during the 𝐁𝐢𝐨𝐄𝐜𝐨𝐧𝐨𝐦𝐲 𝐂𝐨𝐧𝐜𝐥𝐚𝐯𝐞 2026, ABLE instituted the "BioEntrepreneur of the Year Award" to celebrate outstanding entrepreneurial leadership, innovation outcomes, and ecosystem impact across biotechnology sub-sectors. 🎉 We are delighted to recognise Avammune Therapeutics as the 𝐀𝐁𝐋𝐄 𝐁𝐢𝐨𝐄𝐧𝐭𝐫𝐞𝐩𝐫𝐞𝐧𝐞𝐮𝐫 𝐨𝐟 𝐭𝐡𝐞 𝐘𝐞𝐚𝐫 2026.🎉 Founded in 2019, Avammune is advancing a differentiated immuno-oncology pipeline, including its lead ENPP1 inhibitor candidate, AVA-NP-695. Backed by USD 12 million in Series A funding, the company exemplifies scientific excellence, translational focus, and global ambition emerging from India’s biotech ecosystem. hashtag#Congratulations to the Avammune team for embodying the entrepreneurial spirit powering India’s $300 billion bioeconomy vision.

🏆 𝐀𝐁𝐋𝐄 𝐁𝐢𝐨𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫 𝐨𝐟 𝐭𝐡𝐞 𝐘𝐞𝐚𝐫 2026 For the first time, during the 𝐁𝐢𝐨𝐄𝐜𝐨𝐧𝐨𝐦𝐲 𝐂𝐨𝐧𝐜𝐥𝐚𝐯𝐞 2026, ABLE instituted the BioInnovator of the Year Award to recognize transformative innovation, technology scale-up, and sectoral leadership within India’s biotechnology ecosystem. 🎉We are proud to honour @Immuneel_ Therapeutics Pvt. Ltd. as the 𝐀𝐁𝐋𝐄 𝐁𝐢𝐨𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫 𝐨𝐟 𝐭𝐡𝐞 𝐘𝐞𝐚𝐫 2026.🎉 A Bengaluru-based cell and gene therapy pioneer, Immuneel achieved a landmark milestone with the launch of Qartemi, India’s indigenous CAR T-cell therapy approved for adult Non-Hodgkin’s Lymphoma. With an impressive 83.3% overall response rate in the IMAGINE Phase 2 study, Immuneel is redefining personalized cancer care — improving accessibility, affordability, and advancing India’s leadership in next-generation therapeutics. #Congratulations to the Immuneel team for setting new benchmarks in scientific innovation and patient impact.